Skip to main content

Advertisement

SpringerLink
Log in

Role of Transhepatic Arterial Radioembolization in Metastatic Colorectal Cancer

  • Review
  • Interventional Oncology
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

The liver represents the most frequent location of metastatic disease in colorectal cancer (CRC). In oligometastatic disease, while surgery remains the mainstay of treatment, loco-regional therapies allow to locally control tumor progression and prolong survival. There is consensus in the use of transhepatic arterial radioembolization (TARE) in metastatic CRC chemorefractory patients, with liver-only or liver-dominant disease. Beyond this indication, TARE may be considered in other clinical scenarios, such as in the second-line combined with chemotherapy, as a bridge in between different lines of systemic therapies, and as ablative technique under specific circumstances. This paper outlines the current evidence for TARE in mCRC and presents possible future indications and directions

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

    Article  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64. https://doi.org/10.3322/caac.21601.

    Article  PubMed  Google Scholar 

  3. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. https://doi.org/10.1093/annonc/mdw235.

    Article  PubMed  Google Scholar 

  4. Benson AB, Venook AP, Al Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–59. https://doi.org/10.6004/jnccn.2021.0012.

    Article  PubMed  Google Scholar 

  5. Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel Rinkes I, Ledermann JA, et al. European organisation for research and treatment of cancer (EORTC), gastro-intestinal tract cancer group; arbeitsgruppe lebermetastasen und tumoren in der chirurgischen arbeitsgemeinschaft onkologie (ALM-CAO); national cancer research institute colorectal clinical study group (NCRI CCSG). Local treatment of unresectable colorectal liver metastases: Results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9):djx15. https://doi.org/10.1093/jnci/djx015.

    Article  Google Scholar 

  6. Dijkstra M, Nieuwenhuizen S, Puijk RS, Timmer FEF, Geboers B, Schouten EAC, et al. Thermal ablation compared to partial hepatectomy for recurrent colorectal liver metastases: an amsterdam colorectal liver met registry (AmCORE) based study. Cancers (Basel). 2021;13(11):2769. https://doi.org/10.3390/cancers13112769.

    Article  Google Scholar 

  7. Puijk RS, Dijkstra M, van den Bemd BAT, Ruarus AH, Nieuwenhuizen S, Geboers B, et al. Improved outcomes of thermal ablation for colorectal liver metastases: a 10 year analysis from the prospective amsterdam CORE registry (AmCORE). Cardiovasc Intervent Radiol. 2022. https://doi.org/10.1007/s00270-022-03152-9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, et al. EPOCH investigators radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol. 2021. https://doi.org/10.1200/JCO.21.01839.

    Article  PubMed  Google Scholar 

  9. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687–94. https://doi.org/10.1200/JCO.2010.28.5643.

    Article  CAS  PubMed  Google Scholar 

  10. Saxena A, Meteling B, Kapoor J, Golani S, Morris DL, Bester L. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? a large single-center experience of 302 patients. Ann Surg Oncol. 2015;22(3):794–802. https://doi.org/10.1245/s10434-014-4164-x.

    Article  PubMed  Google Scholar 

  11. Kennedy AS, Ball D, Cohen SJ, Cohn M, Coldwell DM, Drooz A, et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J Gastrointest Oncol. 2015;6(2):134–42. https://doi.org/10.3978/j.issn.2078-6891.2014.109.94.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Hickey R, Lewandowski RJ, Prudhomme T, Ehrenwald E, Baigorri B, Critchfield J, et al. 90Y Radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med. 2016;57(5):665–71. https://doi.org/10.2967/jnumed.115.166082.

    Article  CAS  PubMed  Google Scholar 

  13. White J, Carolan-Rees G, Dale M, Morgan HE, Patrick HE, See TC, et al. Analysis of a national programme for selective internal radiation therapy for colorectal cancer liver metastases. Clin Oncol (R Coll Radiol). 2019;31(1):58–66. https://doi.org/10.1016/j.clon.2018.09.002.

    Article  CAS  Google Scholar 

  14. Helmberger T, Golfieri R, Pech M, Pfammatter T, Arnold D, Cianni R, et al. On behalf of the CIRT steering committee; On behalf of the CIRT principal investigators. Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21–35. https://doi.org/10.1007/s00270-020-02642-y.

    Article  PubMed  Google Scholar 

  15. Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014;13(1):27–36. https://doi.org/10.1016/j.clcc.2013.11.010.

    Article  PubMed  Google Scholar 

  16. Dendy MS, Ludwig JM, Kim HS. Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget. 2017;8(23):37912–22. https://doi.org/10.18632/oncotarget.16007.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kurilova I, Beets-Tan RGH, Flynn J, Gönen M, Ulaner G, Petre EN, et al. Factors affecting oncologic outcomes of 90Y radioembolization of heavily pre-treated patients with colon cancer liver metastases. Clin Colorectal Cancer. 2019;18(1):8–18. https://doi.org/10.1016/j.clcc.2018.08.004.

    Article  PubMed  Google Scholar 

  18. Mokkarala M, Noda C, Malone C, Ramaswamy R, Akinwande O. Comparison of response and outcomes of drug-eluting bead chemoembolization (DEB-TACE) versus radioembolization (TARE) for patients with colorectal cancer liver metastases. Anticancer Res. 2019;39(6):3071–7. https://doi.org/10.21873/anticanres.13442.

    Article  CAS  PubMed  Google Scholar 

  19. Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, et al. Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: a meta-analysis. PLoS ONE. 2015;10(10):e0139940. https://doi.org/10.1371/journal.pone.0139940.eCollection.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Levy J, Zuckerman J, Garfinkle R, Acuna SA, Touchette J, Vanounou T, et al. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis. HPB (Oxford). 2018;20(10):905–15. https://doi.org/10.1016/j.hpb.2018.04.001.

    Article  Google Scholar 

  21. Zhao JJ, Tan E, Sultana R, Syn NL, Da Zhuang K, Leong S, et al. Intra-arterial therapy for unresectable colorectal liver metastases: a meta-analysis. J Vasc Interv Radiol. 2021;32(11):1536-1545.e38. https://doi.org/10.1016/j.jvir.2021.05.032.

    Article  PubMed  Google Scholar 

  22. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.

    CAS  PubMed  Google Scholar 

  23. Akinwande O, Dendy M, Ludwig JM, Kim HS. Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a systematic review. Surg Oncol. 2017;26(3):268–75. https://doi.org/10.1016/j.suronc.2017.05.003.

    Article  PubMed  Google Scholar 

  24. Pereira PL, Iezzi R, Manfredi R, Carchesio F, Bánsághi Z, Brountzos E, et al. The CIREL cohort: a prospective controlled registry studying the real-life use of irinotecan-loaded chemoembolisation in colorectal cancer liver metastases: Interim analysis. Cardiovasc Intervent Radiol. 2021;44(1):50–62. https://doi.org/10.1007/s00270-020-02646-8.

    Article  PubMed  Google Scholar 

  25. Walter T, Hawkins NS, Pollock RF, Colaone F, Shergill S, Ross PJ. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. J Cancer Res Clin Oncol. 2020;146(10):2575–87. https://doi.org/10.1007/s00432-020-03315-6.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Brennan VK, Colaone F, Shergill S, Pollock RF. A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. J Med Econ. 2020;23(12):1588–97. https://doi.org/10.1080/13696998.2020.1839273.

    Article  CAS  PubMed  Google Scholar 

  27. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78–85. https://doi.org/10.1002/jso.20141.

    Article  CAS  PubMed  Google Scholar 

  28. Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, et al. FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre randomised phase 3 trials. Lancet Oncol. 2017;18(9):1159–71. https://doi.org/10.1016/S1470-2045(17)30457-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, et al. SIRFLOX and FOXFIRE global trial investigators. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: Combined analysis of two randomized controlled studies. Clin Colorectal Cancer. 2018;17(4):e617–29. https://doi.org/10.1016/j.clcc.2018.06.001.

    Article  PubMed  Google Scholar 

  30. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. RAISE study investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised double-blind, multicenter, phase 3 study. Lancet Oncol. 2015;16(5):499–508. https://doi.org/10.1016/S1470-2045(15)70127-0.

    Article  CAS  PubMed  Google Scholar 

  31. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, et al. ML18147 Study Investigators Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37. https://doi.org/10.1016/S1470-2045(12)70477-1.

    Article  CAS  PubMed  Google Scholar 

  32. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506. https://doi.org/10.1200/JCO.2012.42.8201.

    Article  CAS  PubMed  Google Scholar 

  33. Jeyarajah DR, Doyle MBM, Espat NJ, Hansen PD, Iannitti DA, Kim J, et al. Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. J Gastrointest Oncol. 2020;11(2):443–60. https://doi.org/10.21037/jgo.2020.01.09.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Memeo R, Conticchio M, Deshayes E, Nadalin S, Herrero A, Guiu B, et al. Optimization of the future remnant liver: review of the current strategies in Europe. Hepatobiliary Surg Nutr. 2021;10(3):350–63. https://doi.org/10.21037/hbsn-20-394.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Malhotra A, Liu DM, Talenfeld AD. Radiation segmentectomy and radiation lobectomy: a practical review of techniques. Tech Vasc Interv Radiol. 2019;22(2):49–57. https://doi.org/10.1053/j.tvir.2019.02.003.

    Article  PubMed  Google Scholar 

  36. Garlipp B, Gibbs P, Van Hazel GA, Jeyarajah R, Martin RCG, Bruns CJ, et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. Br J Surg. 2019;106(13):1837–46. https://doi.org/10.1002/bjs.11283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Birgin E, Rasbach E, Seyfried S, Rathmann N, Diehl SJ, Schoenberg SO, et al. Contralateral liver hypertrophy and oncological outcome following radioembolization with 90Y-microspheres: a systematic review. Cancers (Basel). 2020;12(2):294. https://doi.org/10.3390/cancers12020294.

    Article  CAS  Google Scholar 

  38. Ironside N, Bell R, Bartlett A, McCall J, Powell J, Pandanaboyana S. Systematic review of perioperative and survival outcomes of liver resections with and without preoperative portal vein embolization for colorectal metastases. HPB (Oxford). 2017;19(7):559–66. https://doi.org/10.1016/j.hpb.2017.03.003.

    Article  Google Scholar 

  39. Hitpass L, Heise D, Schulze-Hagen M, Pedersoli F, Ulmer F, Amygdalos I, et al. Primary tumor location is a prognostic factor for intrahepatic progression-free survival in patients with colorectal liver metastases undergoing portal vein embolization as preparation for major hepatic surgery. Cancers (Basel). 2020;12(6):1638. https://doi.org/10.3390/cancers12061638.

    Article  CAS  Google Scholar 

  40. Garlipp B, de Baere T, Damm R, Irmscher R, van Buskirk M, Stübs P, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology. 2014;59(5):1864–73. https://doi.org/10.1002/hep.26947.

    Article  CAS  PubMed  Google Scholar 

  41. Khan AS, Garcia-Aroz S, Ansari MA, Atiq SM, Senter-Zapata M, Fowler K, et al. Assessment and optimization of liver volume before major hepatic resection: current guidelines and a narrative review. Int J Surg. 2018;52:74–81. https://doi.org/10.1016/j.ijsu.2018.01.042.

    Article  PubMed  Google Scholar 

  42. Kurilova I, Bendet A, Fung EK, Petre EN, Humm JL, Boas FE, et al. Radiation segmentectomy of hepatic metastases with Y-90 glass microspheres. Abdom Radiol (NY). 2021;46(7):3428–36. https://doi.org/10.1007/s00261-021-02956-6.

    Article  CAS  Google Scholar 

  43. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, et al. Overall survival in phase 3 clinical trials and the surveillance, epidemiology, and end results database in patients with metastatic colorectal cancer, 1986–2016: a systematic review. JAMA Netw Open. 2022;5(5):e2213588. https://doi.org/10.1001/jamanetworkopen.2022.13588.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Kovács A, Bischoff P, Haddad H, Kovács G, Schaefer A, Zhou W, et al. Personalized image-guided therapies for local malignencies: Interdisciplinary options for interventional radiology and interventional radiotherapy. Front Oncol. 2021;11:616058. https://doi.org/10.3389/fonc.2021.616058.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Patel PH, Palma D, McDonald F, Tree AC. The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol (R Coll Radiol). 2019;31(12):824–33. https://doi.org/10.1016/j.clon.2019.05.015.].

    Article  CAS  Google Scholar 

  46. Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA, et al. SIRFLOX study group selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer. 2014;14:897. https://doi.org/10.1186/1471-2407-14-89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Roosen J, Klaassen NJM, Westlund Gotby LEL, Overduin CG, Verheij M, Konijnenberg MW, et al. To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. Eur J Nucl Med Mol Imaging. 2021;48(12):3776–90. https://doi.org/10.1007/s00259-021-05340-0.

    Article  PubMed  PubMed Central  Google Scholar 

  48. van den Hoven AF, Rosenbaum CE, Elias SG, de Jong HW, Koopman M, Verkooijen HM, et al. Insights into the dose-response relationship of radioembolization with resin 90Y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016;57(7):1014–9. https://doi.org/10.2967/jnumed.115.166942.

    Article  CAS  PubMed  Google Scholar 

  49. Sankhla T, Cheng B, Nezami N, Xing M, Sethi I, Bercu Z, et al. Role of resin microsphere Y90 dosimetry in predicting objective tumor response survival and treatment related toxicity in surgically unresectable colorectal liver metastasis: a retrospective single institution study. Cancers (Basel). 2021;13(19):4908. https://doi.org/10.3390/cancers13194908.

    Article  CAS  Google Scholar 

  50. Alsultan AA, van Roekel C, Barentsz MW, Smits MLJ, Kunnen B, Koopman M, et al. Dose-response and dose-toxicity relationships for glass (90)Y radioembolization in patients with liver metastases from colorectal cancer. J Nucl Med. 2021;62(11):1616–23. https://doi.org/10.2967/jnumed.120.255745.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Braat AJAT, Prince JF, van Rooij R, Bruijnen RCG, van den Bosch MAAJ, Lam MGEH. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study. Eur Radiol. 2018;28(3):920–8. https://doi.org/10.1007/s00330-017-4998-2.

    Article  PubMed  Google Scholar 

  52. Smits MLJ, Dassen MG, Prince JF, Braat AJAT, Beijst C, Bruijnen RCG, et al. The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2020;47(4):798–806. https://doi.org/10.1007/s00259-019-04460-y.

    Article  CAS  PubMed  Google Scholar 

  53. Prince JF, van den Bosch MAAJ, Nijsen JFW, Smits MLJ, van den Hoven AF, Nikolakopoulos S, et al. Efficacy of radioembolization with 166Ho-microspheres in salvage patients with liver metastases: a phase 2 study. J Nucl Med. 2018;59(4):582–8. https://doi.org/10.2967/jnumed.117.197194.

    Article  CAS  PubMed  Google Scholar 

  54. van Roekel C, Bastiaannet R, Smits MLJ, Bruijnen RC, Braat AJAT, de Jong HWAM, et al. Dose-effect relationships of (166) Ho radioembolization in colorectal cancer. J Nucl Med. 2021;62(2):272–9. https://doi.org/10.2967/jnumed.120.243832.

    Article  CAS  PubMed  Google Scholar 

  55. Alsultan AA, Barentsz MW, Smits MLJ, Koopman M, Lam MGEH, Rosenbaum CENM. Angiogenesis in (90) Y-radioembolization of colorectal liver metastases. Semin Nucl Med. 2019;49(3):204–10. https://doi.org/10.1053/j.semnuclmed.2019.01.004.

    Article  PubMed  Google Scholar 

  56. Wang C, Park J, Ouyang C, Longmate JA, Tajon M, Chao J, et al. A pilot feasibility study of yttrium-90 liver radioembolization followed by durvalumab and tremelimumab in patients with microsatellite stable colorectal cancer liver metastases. Oncologist. 2020;25(5):382-e776. https://doi.org/10.1634/theoncologist.2019-0924.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was not supported by any funding.

Author information

Authors and Affiliations

  1. Division of Vascular and Interventional Radiology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy

    Irene Bargellini

  2. Department of Interventional Radiology, Pisa University Hospital, Via Paradisa 2, 56126, Pisa, Italy

    Elena Bozzi, Giulia Lorenzoni, Roberto Cioni & Laura Crocetti

  3. Department of Nuclear Medicine, Pisa University Hospital, Via Roma 55, 56126, Pisa, Italy

    Giuseppe Boni & Francesca Bianchi

  4. Department of Medical Physics, Pisa University Hospital, Via Roma 55, 56126, Pisa, Italy

    Claudio Antonio Traino

  5. Department of Medical Oncology, Pisa University Hospital, Via Roma 55, 56126, Pisa, Italy

    Gianluca Masi

Authors
  1. Irene Bargellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Bozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giulia Lorenzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Boni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesca Bianchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Claudio Antonio Traino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gianluca Masi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roberto Cioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Laura Crocetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irene Bargellini.

Ethics declarations

Conflict of interest

Irene Bargellini received speaker honorarium from Terumo Europe, Sirtex, Biocompatibles, Boston Scientific, EISAI-MSD, Ge Healthcare, Bayer, Sobi Giuseppe Boni received speaker honorarium from Terumo Europe. Gianluca Masi received speaker honorarium from Terumo Europe and Sirtex Laura Crocetti received speaker honorarium from Terumo Europe, Boston Scientific, Biomedical, EISAI-MSD. The remaining authors declare no conflicts of interest.

Consent for Publication

For this type of study, consent for publication is not required.

Informed Consent

For this type of study, informed consent is not required.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors. Institutional Review Board (IRB) approval is not needed for this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bargellini, I., Bozzi, E., Lorenzoni, G. et al. Role of Transhepatic Arterial Radioembolization in Metastatic Colorectal Cancer. Cardiovasc Intervent Radiol 45, 1579–1589 (2022). https://doi.org/10.1007/s00270-022-03268-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-022-03268-y

Keywords

Search

Navigation